Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Servier And Pfizer Score Cellectis Cellular Therapy
by Lisa M. Jarvis
November 30, 2015
| A version of this story appeared in
Volume 93, Issue 47
Servier has paid $39.2 million to exercise its option for rights to Cellectis’s UCART19, a cellular therapy on the cusp of Phase I studies in two forms of leukemia. UCART19 uses chimeric antigen receptor T-cell (CART) technology, in which T cells are re-engineered to seek and kill cancer cells. But while other CARTs in development use a cancer patient’s own T cells, UCART19 uses donor cells that enable its use in multiple patients. Servier also has teamed with Pfizer to develop UCART19. Pfizer gets U.S. commercialization rights for the treatment.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X